

# VU Research Portal

## Development of a human tissue engineered hypertrophic scar model

van den Broek, L.J.

2015

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

van den Broek, L. J. (2015). *Development of a human tissue engineered hypertrophic scar model*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### **Take down policy**


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# Chapter 1

## General introduction






This thesis focuses on the development of an *in vivo* like hypertrophic scar model. In this first chapter human skin, scar formation and the existing scar models are introduced. Our own findings are described in the following chapters.

### *Tissue engineering*

Tissue engineering is an emerging multi-disciplinary field that aims to regenerate, replace or restore diseased or damaged tissues with cellular and / or biological and synthetic materials<sup>1</sup>. Over the last years there have been huge advancements in reconstructing tissues and organs *in vitro* (e.g. skin, heart valves, bladder, cartilage)<sup>2-8</sup>. The skin is the most advanced tissue-engineered construct, since organotypic reconstructed skin consisting of both epidermal and dermal layers already exists. Although achieved skin constructs may even contain immune cells e.g. Langerhans Cells in the epidermis and endothelial cells as well as fibroblasts in the dermis<sup>9-13</sup>, they do not yet contain more complex structures for example sweat glands and hair follicles<sup>1,4</sup>. Tissue-engineered skin has *in vivo* and *in vitro* applications. In the clinic it is already used for many years as a replacement for lost skin (e.g. burns, ulcer)<sup>4,14</sup>. As an *in vitro* model reconstructed skin is not only used to study fundamental skin biology processes such as mechanisms involved in wound closure, but it is now also widely implemented in Europe and America as an animal alternative *in vitro* model to identify irritative and corrosive chemicals that can come into contact with the skin<sup>4,15,16</sup>. During the last 10 years, due to increasing pressure from the EU ("Cosmetic Directive") who demanded the replacement, reduction, and refinement of the use of animals models in the cosmetic industry, many new tissue-engineered skin based assays have been developed (e.g. models to distinguish sensitizers and to determine sensitizer potency)<sup>17,18</sup>. *In vitro* skin models can also be modified to mimic skin diseases (e.g. psoriasis, melanoma)<sup>19-21</sup>. These can be used to study the pathogenesis, identify novel drug targets and test new therapeutic strategies. In this thesis we describe the development of a human tissue-engineered skin model to investigate hypertrophic scar formation, which may be used to study the pathogenesis, to test novel drugs and therapeutic strategies. Furthermore such a human physiologically relevant scar model will diminish the use of animals models.

### *Skin*

The skin is the largest organ of the human body and it is constantly exposed to external influences. It is not only a barrier that protects the body against pathogens (e.g. microorganisms, viruses) and UV radiation, but also has an important function in temperature control, water loss and sensation. Depending on the location, the total skin thickness varies from 0.5 mm (eyelids) to 5 mm (the soles of your feet). The skin can be divided into three layers, the epidermis and two layers of connective tissue, the dermis and the




**Figure 1. Schematic structure of human skin.** (Adapted from <http://www.uchospitals.edu/online-library/content=CDR258035>)

hypodermis (or called adipose tissue). The epidermis is separated from the dermis by the basement membrane (Figure 1).

The epidermis is the outermost layer of the human skin and protects the body from the environment. It is a multi-layered cellular structure composed mainly of keratinocytes (up to 95%). Keratinocytes are keratin producing cells which are distributed in layers of increasing differentiation (stratum basale, stratum spinosum, stratum granulosum, stratum lucidum and stratum corneum) (Figure 2). Dividing keratinocytes are found directly on top of the basement membrane in the stratum basale. Merkel cells (sensory cell) and melanocytes are located between the dividing keratinocytes. Melanocytes produce melanin, a pigment that is responsible for the skin colour and protects skin cells from UV radiation. Keratinocytes differentiate, move up to the more outer layers and lose their nucleus (stratum lucidum) during this process. Finally differentiated keratinocytes are hardened, flattened dead cells (stratum corneum) that overlap and create a tough, waterproof protective layer. These cornified keratinocytes are constantly shed from the outer surface of the skin. In the suprabasal layers of the epidermis (stratum spinosum and granulosum) the immune competent Langerhans cells are present.

The dermis lying beneath the epidermis consists mainly of extracellular matrix with cells and vessels distributed throughout it. The extracellular matrix consists predomi-



**Figure 2. Schematic structure of epidermis.** (Adapted from <http://silverbotanicals.com/assets/images/illustrations/structure-of-the-epidermis.jp>)


namely of collagen (70%), elastin (4%), glycosaminoglycans and proteoglycans, which give the dermis strength and elasticity. The dermis can be divided into the papillary dermis (or upper dermis) and the reticular dermis (deeper dermis). The papillary dermis (thickness 300–400  $\mu\text{m}$ ) consists of a network of relatively thin fibers of connective tissue, is more crowded with cells (e.g. endothelial cells, fibroblasts) than the reticular dermis and the main function is supporting the epidermis<sup>22</sup>. The reticular dermis consists of a more dense and thick connective tissue. The main cells that populate the dermis are the connective tissue producing mesenchymal cells, called fibroblasts. It also contains nerves, sweat glands, sebaceous glands, hair follicles, lymphatic vessels, microvascular vessels (composed of endothelial cells) and immune cells (e.g. macrophages, dermal dendritic cells, lymphocytes).

The hypodermis lies between the dermis and underlying tissues (e.g. bone, muscle) and organs. It serves to fasten the skin to the underlying tissues, provides thermal insulation, energy reserve and absorbs shocks from impacts to the skin. It consists of adipose tissue, hair follicles (roots), nerves, blood vessels and lymphatic vessels. Important cell types are the adipocytes (fat cells) and adipose tissue-derived mesenchymal cells.




*Human cutaneous wound healing*

Cutaneous wound healing is an interactive process characterized by a sequence of events that begin directly after injury. It can be divided into four phases; hemostasis, inflammation, proliferation and remodeling (respectively Figure 3a, b, c, d). It should



**Figure 3. Schematic overview of human cutaneous wound healing.** (a) A blood clot is formed. Platelets release inflammatory mediators which attract immune cells into the wound bed (Hemostasis phase). (b) Neutrophils and macrophages migrate into the wound bed to kill bacteria and to secrete more mediators (Inflammation phase). (c) Fibroblasts and endothelial cells are attracted to the wound site, proliferate and deposit extracellular matrix and form new blood vessels, respectively. Keratinocytes start to migrate and proliferate to re-epithelialize the wound (proliferation phase) (d) Fibroblasts differentiate into myofibroblasts, leading to wound contraction and increased extra cellular matrix deposition. The wound is completely closed by a new epidermis. In order to further repair and strengthen the dermis, the newly formed collagen is reorganized and cross-linked (proliferation and remodelling phase). (Adapted from Werner et al<sup>114</sup>)



**Figure 4. Overlapping phases of human cutaneous wound healing.**

be noted that these phases overlap in time (Figure 4) and are characterized by multiple interactions.

The first phase hemostasis starts directly upon injury when bleeding occurs as a result of the disruption of blood vessels. To prevent blood loss the vessels constrict within seconds. Platelets are activated and undergo adhesion, aggregation and at the same time release soluble wound healing mediators. These mediators induce further platelet aggregation and activation of the coagulation pathway. Prothrombin is converted into thrombin and this in turn converts soluble fibrinogen to insoluble fibrin, which leads to a fibrin clot<sup>23,24</sup>. The fibrin clot further contains fibrinectin, vitronectin and thrombospondin. Besides forming a temporary cover for the wound, the clot also serves as a network for cells migrating into the wound bed and as a reservoir of growth factors and cytokines which are required during the later stages of the wound healing process. Platelets influence wound repair by releasing chemotactic factors for infiltration of leukocytes and factors strongly implicated in wound repair (e.g. TGF- $\beta$ 1, PDGF and VEGF)<sup>23-25</sup>.

Inflammation, the second phase, is crucial to neutralize infections. As mentioned earlier, cytokines and growth factors released by platelets and injured skin resident cells attract leukocytes into the wound bed. Neutrophils are the first immune cells that arrive at the wound bed in high numbers. Once in the wound bed, neutrophils produce a wide variety of proteinases and reactive oxygen species to kill bacteria and clear damaged matrix proteins<sup>23,26</sup>. Neutrophil infiltration normally lasts for only a few days. At a later stage during inflammation (day 3-5), when the number of neutrophils declines, macrophages (blood-derived monocytes) are the predominate cell type. Monocytes infiltrate the wound bed in response to chemoattractants (e.g. CCL2 and IL-1) released by platelets and endothelial cells and differentiate into macrophages<sup>27,28</sup>. Macrophages can become activated in response to signals present in the wound bed or to pathogens. Macrophages have been described to display two different functional phenotypes which can broadly be divided into M1 (classically activated) and M2 (alternatively activated) macrophages. However this is an oversimplification since *in vivo* macrophages have dynamic and plastic phenotypes (continuum between the M1 and M2 extremes)



that change with the local environment<sup>28,29</sup>. During inflammation, macrophages are described to have a more M1 phenotype<sup>28</sup>. They remove senescent cells and debris in the wound bed (innate immune system), present antigens of pathogens to T-lymphocytes (adapted immune system) and produce large amounts of cytokines and growth factors to further amplify the inflammatory response<sup>23,28,29</sup>. M2 macrophages are more associated with tissue repair and fibrosis.


During the third phase (proliferation) damaged and/or lost tissue is regenerated. In contrast to the inflammation phase, where M1 macrophages predominate, during the proliferation phase M2 macrophages predominate. They suppress inflammatory responses by secreting factors like IL-10 and TGF- $\beta$ 1 and promote angiogenesis, tissue remodeling and repair<sup>28,29</sup>. Fibroblasts in surrounding intact dermis begin to proliferate, migrate into the fibrin clot (provisional matrix) and start to deposit their own extracellular matrix (called granulation tissue, which mainly consists of collagen III, collagen I, fibronectin, glycosaminoglycans and proteoglycans)<sup>30</sup>. Under influence of TGF- $\beta$  and mechanical stiffness in the wound bed a subgroup of the fibroblasts differentiate into myofibroblasts, which express  $\alpha$ -smooth muscle actin in their stress fibres<sup>31</sup>. Myofibroblasts induces wound contraction (contributing to wound closure) and also deposit extracellular matrix<sup>23,32</sup>. At the same time, wound microvasculature is reconstructed in order to re-establish the nutrient and oxygen supply to regenerated tissue. Endothelial cells sprout from pre-existing vessels into the wound matrix. This sprouting is stimulated by e.g. VEGF, FGF2 and TGF- $\beta$ 1, which are mainly produced by keratinocytes, macrophages, platelets and fibroblasts, to form new vessels<sup>30</sup>. The formation of granulation tissue into an open wound allows keratinocytes (coming from the basal layer of the wound edge and/or epidermal progenitors cells from hair follicles) to proliferate and migrate across the new tissue and form a new barrier between the wound and the environment resulting in re-epithelialization. This is mainly stimulated by factors (e.g. EGF, KGF TGF- $\alpha$ ) secreted by macrophages, platelets and fibroblasts<sup>23,33</sup>.

During remodeling, the last phase of wound healing, cell proliferation decreases and the levels of collagen production and degradation equalize. As a result the nutrient and oxygen demand decreases and unnecessary microvessels formed in granulation tissue regress<sup>30</sup>. Cells that are no longer needed (e.g. myofibroblasts and macrophages) undergo apoptosis or leave the wound region<sup>34,35</sup>. Collagen III, which is prevalent in granulation tissue, is replaced by the stronger collagen I, which results in increased strength of the extracellular matrix. The extracellular matrix is further strengthened by rearranging, cross-linking and aligning originally disorganized collagen fibers<sup>23,36</sup>. Matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs) are described to be important regulators of proteolytic activity during this process and are mainly produced by macrophages, fibroblasts and endothelial cells<sup>37</sup>. At the end the remodeling phase, restoration of skin integrity has been achieved. However, the tensile strength of the

healed wound is only approximately 80% that of normal unwounded tissue. This tissue is called a normotrophic scar.

#### *Abnormal scar formation*

Wound healing of full thickness wounds generally leads to the formation of a normotrophic scar (Figure 5a). The normotrophic scar is hardly visible since it is smooth, pale and flattened. This is considered to be the best clinical endpoint. However abnormal wound healing can lead to the development of an abnormal raised scar (hypertrophic scar or keloid scar (Figure 5b&c)). Both abnormal scars can cause significant physiological (limited joint mobility in particular with hypertrophic scars) and psychological (especially the face) problems leading to diminished quality of life<sup>38,39</sup>. Unfortunately both scars are therapy-resistant with high recurrence rates after excision<sup>40-42</sup>. Below, these two types of scar will be described followed by the pathogenesis of scar formation.



**Figure 5. Macroscopic photographs of different scar tissues.** (a) Normotrophic scar developed after incision wound (sternum) (b) Hypertrophic scar developed after incision wound (sternum) (c) Keloid scar formed from pustule (sternum). Bars = 1 cm

*Keloid scar versus Hypertrophic scar*

The differentiation between young hypertrophic and keloid scars remains clinically difficult. Both scars are red, firm and raised lesions, that arise from an overproduction of extracellular matrix<sup>43</sup>. However there are clear clinical, morphological and epidemiological differences described between hypertrophic and keloid scars. Morphologically, collagen fibers are flatter and thinner and more microvessels are present in hypertrophic compared to keloid scars<sup>39,44,45</sup>. A clinical difference between the two scars is that hypertrophic scars generally remain confined to the borders of the original lesion, whereas keloid scars show an invasive growth in the surrounding normal skin<sup>46</sup>. Hypertrophic scars are more often formed on locations with high tension (e.g. shoulders, knees, presternum)<sup>47-49</sup>, but can form anywhere on the human body. Generally they start to develop within 4-8 weeks after injury, continue to grow for up to 6 to 12 months, mature and then may diminish in time (years). They are found in almost all patients when trauma is extensive and / or deep enough (34-64% undergoing standard surgical procedures<sup>50,51</sup> and even up to 91% following large deep burn injury<sup>52,53</sup>). In contrast, keloid scars can develop after minor injury (e.g. pustule or piercing), even years after the initial injury and almost never regress. Keloid scars have clear predilection sites (shoulders, chest, earlobes, cheeks and upper arms)<sup>44,46</sup> and the recurrence rates of keloid scars after incision are higher than of hypertrophic scars<sup>54</sup>. Keloid scars are less prevalent than hypertrophic scars, but are more common among the darker pigmented skin population (up to 6-10% in African populations) than north European Caucasian population (0.1%)<sup>39,55</sup>. In addition to this, genetic predisposition of keloid scar formation is supported by reports that >50% of people developing keloid scars have a family history of keloids and that there is a prevalence of keloid scars in twins<sup>38,56</sup>.

*Pathogenesis*

The differences between hypertrophic and keloid scars suggest a difference in the underlying pathology. Despite abundant literature the pathogenesis underlying hypertrophic and keloid scars remains largely unknown. In literature a clear distinction between the pathogenesis of the two adverse is rarely made. The pathogenesis described below focuses mainly on hypertrophic scar formation.

Normally during hemostasis, fibronectin (component fibrin clot) expression decreases within a few days after injury. However during hypertrophic scar formation fibronectin remains elevated for several weeks<sup>57</sup>. In line with this, reports show that inadequate degradation of the fibrin clot might lead to fibrosis<sup>58,59</sup>. An increased and prolonged inflammatory response has been linked to hypertrophic scar formation<sup>60,61</sup>, but literature often shows contradictory results. For instance mast cells are described to be both increased<sup>62</sup> or present in equal numbers<sup>63</sup> in hypertrophic scars compared to normotrophic scars. The development of a T-helper2 response is strongly linked to fibrosis<sup>52,60</sup>. Furthermore

an increased number of Langerhans cells are found in epidermis of hypertrophic scars<sup>63</sup>. Hypertrophic scars are more often seen after delayed wound closure<sup>48</sup> and the resulting hypertrophic scar shows increased numbers of microvessels<sup>45</sup>, increased extracellular matrix (ECM) deposition and decreased apoptosis especially of fibroblasts and myofibroblasts compared to normotrophic scars<sup>61,64</sup>. Abnormal expression of proteoglycans and MMPs/TIMPS (e.g. decreased decorin, MMP1/9 and increased TIMP-1, biglycan and versican) which may lead to increased proliferation and matrix production and reduced matrix breakdown also suggests an altered ECM remodeling in hypertrophic compared to normotrophic scar formation<sup>60,61</sup>. Especially the increased levels of fibrogenic growth factors TGF $\beta$ 1, and to lesser extent PDGF and IGF-1 have been linked to adverse scar formation<sup>46,52</sup>. TGF $\beta$ 1 is a chemoattractant for immune cells and fibroblasts, mitogenic for fibroblasts and facilitates differentiation of fibroblasts into myofibroblasts probably leading to increased matrix production<sup>52,60,65</sup>. It has been found to be increased in keloid and hypertrophic scar fibroblasts<sup>66,67</sup> and the transition from scar-less fetal wound healing to adult scarring is also thought to be TGF $\beta$ 1 dependent (also TGF $\beta$ 3)<sup>61,68</sup>.

#### *Hypertrophic and keloid scar models*

Naturally, *in vivo* human patient studies most accurately reflect human wound healing. However exploring the pathogenesis of adverse scar formation in human is cumbersome. This is due to ethical issues and logistical problems with regards to a defined experimental set-up and obtaining samples for analysis and also due to patient variation with regards to extent and duration of trauma. Research into the pathogenesis of adverse scar formation has been further complicated by the lack of suitable adverse scar models. Adverse scar models are used with varying degrees of success to represent human scars and are discussed below.

#### *Animal models*

There are a large number of studies describing pigs, mice, rats, rabbits, and other animals as models to investigate hypertrophic scarring or keloid scar formation<sup>68-78</sup>. Some studies induce a scar by standardized trauma (e.g. excision wounds<sup>1,4,79</sup>). Unfortunately, most often no clear distinction between normotrophic scar formation, hypertrophic scar formation and keloid scar formation is made<sup>55</sup>. Also the skin physiology, immunology and therefore the wound healing process is markedly different in humans compared to animals<sup>80-83</sup>. In line with this, animals do not develop scars which are comparable to adverse scars in humans<sup>81,82</sup>. Other studies describe animal models where human skin or scar tissue is grafted onto the animal. This led to the development of a hypertrophic scar model in which a healthy human split-thickness skin graft is grafted onto the back of a nude mouse where it developed into a red and thickened scar showing similarities with hypertrophic scars in humans<sup>69,84,85</sup>. An animal model to study keloid pathogenesis

was constructed in a similar manner by transplanting human keloid scar onto nude mice<sup>72,74,86,87</sup>. A limitation for the keloid scar models is the limited availability of human keloid scar. A limitation for both adverse scar models is that the immune component of wound healing and scar formation is severely compromised due to the immune deficiency of the nude mouse. This is supported by reports showing that mouse models in general poorly mimic human inflammatory events (e.g. burn wound trauma)<sup>83</sup>. The only human immune cells present are derived from the transplanted skin itself as human immune cells from the blood are absent<sup>88</sup>. Until now there is no optimal animal model to study adverse scar formation.

#### *In vitro scar models*

*In vitro* cell culture models have also been used to study scar pathogenesis. The most basic models consist of conventional monolayers of cells where normal and scar derived fibroblasts or keratinocytes are compared<sup>89-98</sup>. By introducing a scratch (wound) in the monolayer migration could be studied<sup>99</sup> next to proliferation and production of soluble wound healing mediators. These monolayer cultures are simple, fast, easy to perform and inexpensive but skin consists of more than one cell type. This led to (in)direct co-cultures of keratinocytes and fibroblasts which enabled the study of keratinocyte-fibroblast interactions on adverse scar formation<sup>93,94,100,101</sup>. However, the cultures do not mimic the 3D *in vivo* like situation and therefore missed physiological relevance. Indeed, it was noticed that the introduction of a more physiologically relevant 3D environment (collagen or fibrin gel) and mechanical load positively influenced the behavior of fibroblasts towards the scar phenotype<sup>102-105</sup>. A more *in vivo*-like situation was created by enabling fibroblasts to produce their own matrix with on top a reconstructed fully differentiated epidermis of hypertrophic scar derived keratinocytes<sup>106,107</sup>. This model showed a few characteristics of an adverse scar (e.g. dermal thickness, epidermal thickness, collagen I) and emphasize the role of keratinocytes in hypertrophic scar formation. Also a 3D skin equivalent model has been described using keloid scar fibroblasts in combination with normal skin derived keratinocytes showing increased collagen production and contraction compared to skin equivalent using normal skin derived fibroblast and keratinocytes<sup>108,109</sup>. This is a limitation in the model since keloid keratinocytes have been described to be intrinsically different to normal skin derived keratinocytes<sup>90,93,100,110-113</sup>. Major limitations of these models are their dependence on excised scar tissue, the lack of robust validated biomarkers for testing therapeutics and the lack of an immune component.

#### *Outline and aim*

Many attempts have been performed to develop an *in vivo* like hypertrophic scar model. Until now no robust and physiologically relevant *in vitro* hypertrophic scar model ex-

ists for *in vitro* testing of therapeutics with multiple defined scar forming parameters. With increasing pressure from the EU (Directive 86/609/EEC) who strongly stimulate the replacement, reduction, and refinement of the use of animals models, there is an urgent need to develop such a hypertrophic scar model. Once established the model could be used to study the pathogenesis of hypertrophic scar formation. This in turn should facilitate identifying and testing new therapeutics, and thus lead to novel treatment strategies. Therefore the aim of this study was to develop and validate an *in vitro* full-thickness human tissue-engineered hypertrophic scar model.

In chapter 2 we compared the transcription of genes and proteins involved in inflammation, angiogenesis and granulation tissue formation in patients forming hypertrophic scars rather than normotrophic scars to gain more knowledge of the pathogenesis of hypertrophic scar formation and to identify markers for the hypertrophic scar model. In chapter 3 we studied the influence of burn wound exudates (which mimic the burn wound bed) on adipose tissue-derived mesenchymal stem cells, dermal fibroblasts and keratinocytes which may be important for the use in skin tissue engineering constructs and wound healing. In particular CCL27, a skin specific chemokine highly present in burn wound exudates, was investigated (Chapter 3&4).

During wound healing a hypoxic environment (< 5% oxygen) is present until neo-vascularization occurs and this hypoxia may influence scar formation. In order to study this in chapter 5 adipose tissue-derived mesenchymal stem cells were chosen since they reside deep in the cutaneous wound bed which, when exposed, often heals with hypertrophic scar formation. Furthermore these stem cells maintain their capacity to differentiate into osteogenic, chondrogenic, myogenic and cardiomyocytic lineages in culture. Importantly, due to their availability and wide range of applications, adipose tissue-derived mesenchymal stem cells have great potential within the field of (skin) tissue engineering. Also, *in vivo*, fibrin forms a temporary extracellular matrix for neo-vascularization. Naturally occurring fibrinogen variants alter functional and molecular mechanisms of endothelial cells. High molecular weight fibrin increases neo-vascularization *in vitro* and *in vivo* compared to low molecular weight fibrin and unfractionated fibrin. The question arises whether the naturally occurring fibrinogen variants might alter mesenchymal stem cell expansion and differentiation and therefore scar forming properties. If this is the case then they need to be considered as a component of the dermal matrix when constructing the hypertrophic scar model. Therefore in chapter 5 the effect of oxygen tension (1% compared to 20%) and naturally occurring fibrinogen variants on adipose tissue-derived mesenchymal stem cell expansion and differentiation was studied.

Whereas chapters 2–5 present a detailed selection of potential biomarkers and cell types for incorporation into a hypertrophic scar model, chapters 6 and 7 describe two different tissue-engineered hypertrophic scar models. Chapter 6 describes a model of

primary cells isolated directly from excised scar tissue, which can be used to reconstruct 3D scar *in vitro*. Using this tissue-engineered scar model parameters were identified which distinguish normal skin and normotrophic scars from abnormal scars, and hypertrophic scars from keloid scars. These models are dependent on excised scar tissue, which is limited. Therefore the second hypertrophic scar model described in chapter 7 describes the use of keratinocytes and ASC obtained from healthy adult abdominal skin which is routinely removed in standard corrective surgical procedures and is a readily available source of cells for tissue engineering (Chapter 7).

In chapter 8 the progress, limitations and the future challenges in the field of human hypertrophic and keloid scar models are discussed. The major findings from this thesis are discussed in chapter 9.



## REFERENCES

1. Metcalfe A D, Ferguson M W Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. *J R Soc Interface* 2007; 4: 413-437.
2. Adamowicz J, Kowalczyk T, Drewna T Tissue engineering of urinary bladder - current state of art and future perspectives. *Cent European J Urol* 2013; 66: 202-206.
3. Bhattacharjee M, Coburn J, Centola M et al. Tissue engineering strategies to study cartilage development, degeneration and regeneration. *Adv Drug Deliv Rev* 2014.
4. Groeber F, Holeiter M, Hampel M et al. Skin tissue engineering--in vivo and in vitro applications. *Adv Drug Deliv Rev* 2011; 63: 352-366.
5. Lueders C, Jastram B, Hetzer R et al. Rapid manufacturing techniques for the tissue engineering of human heart valves. *Eur J Cardiothorac Surg* 2014.
6. Matsuura K, Utoh R, Nagase K et al. Cell sheet approach for tissue engineering and regenerative medicine. *J Control Release* 2014.
7. Muylaert D E, Fledderus J O, Bouten C V et al. Combining tissue repair and tissue engineering; bioactivating implantable cell-free vascular scaffolds. *Heart* 2014.
8. Sloff M, Simaioforidis V, de V R et al. Tissue Engineering of the Bladder-Reality or Myth? A Systematic Review. *J Urol* 2014.
9. Auxenfans C, Lequeux C, Perrusel E et al. Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents. *J Tissue Eng Regen Med* 2012; 6: 512-518.
10. Bechetoille N, Dezutter-Dambuyant C, Damour O et al. Effects of solar ultraviolet radiation on engineered human skin equivalent containing both Langerhans cells and dermal dendritic cells. *Tissue Eng* 2007; 13: 2667-2679.
11. Gibbs S, van den Hoogenband H M, Kirtschig G et al. Autologous full-thickness skin substitute for healing chronic wounds. *Br J Dermatol* 2006; 155: 267-274.
12. Herman I M, Leung A Creation of human skin equivalents for the in vitro study of angiogenesis in wound healing. *Methods Mol Biol* 2009; 467: 241-248.
13. Ouwehand K, Spiekstra S W, Waaijman T et al. Technical advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. *J Leukoc Biol* 2011; 90: 1027-1033.
14. Blok C S, Vink L, de Boer E M et al. Autologous skin substitute for hard-to-heal ulcers: retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized setting. *Wound Repair Regen* 2013; 21: 667-676.
15. Fentem J H, Archer G E, Balls M et al. The ECVAM International Validation Study on In Vitro Tests for Skin Corrosivity. 2. Results and Evaluation by the Management Team. *Toxicol In Vitro* 1998; 12: 483-524.
16. Tweats D J, Scott A D, Westmoreland C et al. Determination of genetic toxicity and potential carcinogenicity in vitro--challenges post the Seventh Amendment to the European Cosmetics Directive. *Mutagenesis* 2007; 22: 5-13.
17. Teunis M A, Spiekstra S W, Smits M et al. International ring trial of the epidermal equivalent sensitizer potency assay: reproducibility and predictive-capacity. *ALTEX* 2014; 31: 251-268.
18. dos Santos G G, Spiekstra S W, Sampat-Sardjoepersad S C et al. A potential in vitro epidermal equivalent assay to determine sensitizer potency. *Toxicol In Vitro* 2011; 25: 347-357.

19. Commandeur S, Sparks S J, Chan H L et al. In-vitro melanoma models: invasive growth is determined by dermal matrix and basement membrane. *Melanoma Res* 2014; 24: 305-314.
20. Bracke S, Desmet E, Guerrero-Aspizua S et al. Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model. *Arch Dermatol Res* 2013; 305: 501-512.
21. van den Bogaard E H, Tjabringa G S, Joosten I et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases. *J Invest Dermatol* 2014; 134: 719-727.
22. Sorrell J M, Caplan A I Fibroblast heterogeneity: more than skin deep. *J Cell Sci* 2004; 117: 667-675.
23. Broughton G, Janis J E, Attinger C E The basic science of wound healing. *Plast Reconstr Surg* 2006; 117: 12S-34S.
24. Li J, Chen J, Kirsner R Pathophysiology of acute wound healing. *Clin Dermatol* 2007; 25: 9-18.
25. Martin P, Leibovich S J Inflammatory cells during wound repair: the good, the bad and the ugly. *Trends Cell Biol* 2005; 15: 599-607.
26. Gillitzer R, Goebeler M Chemokines in cutaneous wound healing. *J Leukoc Biol* 2001; 69: 513-521.
27. DiPietro L A, Polverini P J, Rahbe S M et al. Modulation of JE/MCP-1 expression in dermal wound repair. *Am J Pathol* 1995; 146: 868-875.
28. Mahdavian D B, van der Veer W M, van E M et al. Macrophages in skin injury and repair. *Immunobiology* 2011; 216: 753-762.
29. Brown B N, Ratner B D, Goodman S B et al. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. *Biomaterials* 2012; 33: 3792-3802.
30. Greaves N S, Ashcroft K J, Baguneid M et al. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. *J Dermatol Sci* 2013; 72: 206-217.
31. Klingberg F, Hinz B, White E S The myofibroblast matrix: implications for tissue repair and fibrosis. *J Pathol* 2013; 229: 298-309.
32. Barrientos S, Stojadinovic O, Golinko M S et al. Growth factors and cytokines in wound healing. *Wound Repair Regen* 2008; 16: 585-601.
33. Lawrence W T, Diegelmann R F Growth factors in wound healing. *Clin Dermatol* 1994; 12: 157-169.
34. Greenhalgh D G The role of apoptosis in wound healing. *Int J Biochem Cell Biol* 1998; 30: 1019-1030.
35. Johnson A, DiPietro L A Apoptosis and angiogenesis: an evolving mechanism for fibrosis. *FASEB J* 2013; 27: 3893-3901.
36. Reinke J M, Sorg H Wound repair and regeneration. *Eur Surg Res* 2012; 49: 35-43.
37. Martins V L, Caley M, O'Toole E A Matrix metalloproteinases and epidermal wound repair. *Cell Tissue Res* 2013; 351: 255-268.
38. Bayat A, McGrouther D A, Ferguson M W Skin scarring. *BMJ* 2003; 326: 88-92.
39. Verhaegen P D, van Zuijlen P P, Pennings N M et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis. *Wound Repair Regen* 2009; 17: 649-656.
40. Wang X Q, Liu Y K, Qing C et al. A review of the effectiveness of antimetabolic drug injections for hypertrophic scars and keloids. *Ann Plast Surg* 2009; 63: 688-692.
41. Roques C, Teot L The use of corticosteroids to treat keloids: a review. *Int J Low Extrem Wounds* 2008; 7: 137-145.
42. Greenhalgh D G Consequences of excessive scar formation: dealing with the problem and aiming for the future. *Wound Repair Regen* 2007; 15 Suppl 1: S2-S5.

43. Ehrlich H P, Desmouliere A, Diegelmann R F et al. Morphological and immunochemical differences between keloid and hypertrophic scar. *Am J Pathol* 1994; 145: 105-113.
44. Burd A, Huang L Hypertrophic response and keloid diathesis: two very different forms of scar. *Plast Reconstr Surg* 2005; 116: 150e-157e.
45. van der Veer W M, Niessen F B, Ferreira J A et al. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. *Wound Repair Regen* 2011; 19: 292-301.
46. Niessen F B, Spauwen P H, Schalkwijk J et al. On the nature of hypertrophic scars and keloids: a review. *Plast Reconstr Surg* 1999; 104: 1435-1458.
47. Brody G S, Peng S T, Landel R F The etiology of hypertrophic scar contracture: another view. *Plast Reconstr Surg* 1981; 67: 673-684.
48. Deitch E A, Wheelahan T M, Rose M P et al. Hypertrophic burn scars: analysis of variables. *J Trauma* 1983; 23: 895-898.
49. Gangemi E N, Gregori D, Berchiolla P et al. Epidemiology and risk factors for pathologic scarring after burn wounds. *Arch Facial Plast Surg* 2008; 10: 93-102.
50. van der Veer W M, Ferreira J A, de Jong E H et al. Perioperative conditions affect long-term hypertrophic scar formation. *Ann Plast Surg* 2010; 65: 321-325.
51. Niessen F B, Spauwen P H, Robinson P H et al. The use of silicone occlusive sheeting (Sil-K) and silicone occlusive gel (Epiderm) in the prevention of hypertrophic scar formation. *Plast Reconstr Surg* 1998; 102: 1962-1972.
52. Gauglitz G G, Kortling H C, Pavicic T et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. *Mol Med* 2011; 17: 113-125.
53. Kose O, Waseem A Keloids and hypertrophic scars: are they two different sides of the same coin? *Dermatol Surg* 2008; 34: 336-346.
54. Mustoe T A, Cooter R D, Gold M H et al. International clinical recommendations on scar management. *Plast Reconstr Surg* 2002; 110: 560-571.
55. van den Broek L J, Limandjaja G C, Niessen F B et al. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective. *Exp Dermatol* 2014; 23: 382-386.
56. BLOOM D Heredity of keloids; review of the literature and report of a family with multiple keloids in five generations. *N Y State J Med* 1956; 56: 511-519.
57. Sible J C, Eriksson E, Smith S P et al. Fibronectin gene expression differs in normal and abnormal human wound healing. *Wound Repair Regen* 1994; 2: 3-19.
58. Clark R A Fibrin and wound healing. *Ann N Y Acad Sci* 2001; 936: 355-367.
59. Tuan T L, Wu H, Huang E Y et al. Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures. *Am J Pathol* 2003; 162: 1579-1589.
60. Armour A, Scott P G, Tredget E E Cellular and molecular pathology of HTS: basis for treatment. *Wound Repair Regen* 2007; 15 Suppl 1: S6-17.
61. van der Veer W M, Bloemen M C, Ulrich M M et al. Potential cellular and molecular causes of hypertrophic scar formation. *Burns* 2009; 35: 15-29.
62. Tredget E E, Shankowsky H A, Pannu R et al. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. *Plast Reconstr Surg* 1998; 102: 1317-1328.
63. Niessen F B, Schalkwijk J, Vos H et al. Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. *J Pathol* 2004; 202: 121-129.

64. Sarrazy V, Billet F, Micallef L et al. Mechanisms of pathological scarring: role of myofibroblasts and current developments. *Wound Repair Regen* 2011; 19 Suppl 1: s10-s15.
65. Profyris C, Tziotzios C, Do V, I Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. *J Am Acad Dermatol* 2012; 66: 1-10.
66. Wang R, Ghahary A, Shen Q et al. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. *Wound Repair Regen* 2000; 8: 128-137.
67. Lee TY, Chin G S, Kim W J et al. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. *Ann Plast Surg* 1999; 43: 179-184.
68. Ferguson M W, O'Kane S Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. *Philos Trans R Soc Lond B Biol Sci* 2004; 359: 839-850.
69. Momtazi M, Kwan P, Ding J et al. A nude mouse model of hypertrophic scar shows morphologic and histologic characteristics of human hypertrophic scar. *Wound Repair Regen* 2013; 21: 77-87.
70. Kloeters O, Tandara A, Mustoe T A Hypertrophic scar model in the rabbit ear: a reproducible model for studying scar tissue behavior with new observations on silicone gel sheeting for scar reduction. *Wound Repair Regen* 2007; 15 Suppl 1: S40-S45.
71. Zhu K Q, Carrougner G J, Gibran N S et al. Review of the female Duroc/Yorkshire pig model of human fibroproliferative scarring. *Wound Repair Regen* 2007; 15 Suppl 1: S32-S39.
72. Kischer C W, Pindur J, Shetlar M R et al. Implants of hypertrophic scars and keloids into the nude (athymic) mouse: viability and morphology. *J Trauma* 1989; 29: 672-677.
73. Aarabi S, Bhatt K A, Shi Y et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. *FASEB J* 2007; 21: 3250-3261.
74. Estrem S A, Domayer M, Bardach J et al. Implantation of human keloid into athymic mice. *Laryngoscope* 1987; 97: 1214-1218.
75. Hochman B, Vilas Boas F C, Mariano M et al. Keloid heterograft in the hamster (*Mesocricetus auratus*) cheek pouch, Brazil. *Acta Cir Bras* 2005; 20: 200-212.
76. Shetlar M R, Shetlar C L, Hendricks L et al. The use of athymic nude mice for the study of human keloids. *Proc Soc Exp Biol Med* 1985; 179: 549-552.
77. Wang H, Luo S Establishment of an animal model for human keloid scars using tissue engineering method. *J Burn Care Res* 2013; 34: 439-446.
78. Celeste C J, Deschene K, Riley C B et al. Regional differences in wound oxygenation during normal healing in an equine model of cutaneous fibroproliferative disorder. *Wound Repair Regen* 2011; 19: 89-97.
79. Gallant-Behm C L, Olson M E, Hart D A Cytokine and growth factor mRNA expression patterns associated with the hypercontracted, hyperpigmented healing phenotype of red duroc pigs: a model of abnormal human scar development? *J Cutan Med Surg* 2005; 9: 165-177.
80. Hillmer M P, MacLeod S M Experimental keloid scar models: a review of methodological issues. *J Cutan Med Surg* 2002; 6: 354-359.
81. Ramos M L, Gagnani A, Ferreira L M Is there an ideal animal model to study hypertrophic scarring? *J Burn Care Res* 2008; 29: 363-368.
82. Seo B F, Lee J Y, Jung S N Models of Abnormal Scarring. *Biomed Res Int* 2013; 2013: 423147.
83. Seok J, Warren H S, Cuenca A G et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* 2013; 110: 3507-3512.
84. Wang J, Ding J, Jiao H et al. Human hypertrophic scar-like nude mouse model: characterization of the molecular and cellular biology of the scar process. *Wound Repair Regen* 2011; 19: 274-285.

85. Yang D Y, Li S R, Wu J L et al. Establishment of a hypertrophic scar model by transplanting full-thickness human skin grafts onto the backs of nude mice. *Plast Reconstr Surg* 2007; 119: 104-109.
86. Ishiko T, Naitoh M, Kubota H et al. Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers. *J Dermatol* 2013; 40: 380-383.
87. Waki E Y, Crumley R L, Jakowatz J G Effects of pharmacologic agents on human keloids implanted in athymic mice. A pilot study. *Arch Otolaryngol Head Neck Surg* 1991; 117: 1177-1181.
88. Butler P D, Longaker M T, Yang G P Current progress in keloid research and treatment. *J Am Coll Surg* 2008; 206: 731-741.
89. De F B, Garbi C, Santoriello M et al. Differential apoptosis markers in human keloids and hypertrophic scars fibroblasts. *Mol Cell Biochem* 2009; 327: 191-201.
90. Hahn J M, Glaser K, McFarland K L et al. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. *Wound Repair Regen* 2013; 21: 530-544.
91. Honardoust D, Ding J, Varkey M et al. Deep dermal fibroblasts refractory to migration and decorin-induced apoptosis contribute to hypertrophic scarring. *J Burn Care Res* 2012; 33: 668-677.
92. Huang L, Cai Y J, Lung I et al. A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. *J Plast Reconstr Aesthet Surg* 2013.
93. Lim C P, Phan T T, Lim I J et al. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. *J Invest Dermatol* 2009; 129: 851-861.
94. Phan T T, Sun L, Bay B H et al. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: therapeutic implication for excessive scarring. *J Trauma* 2003; 54: 1212-1224.
95. Suarez E, Syed F, Alonso-Rasgado T et al. Up-regulation of tension-related proteins in keloids: knockdown of Hsp27, alpha2beta1-integrin, and PAI-2 shows convincing reduction of extracellular matrix production. *Plast Reconstr Surg* 2013; 131: 158e-173e.
96. Syed F, Bayat A Superior effect of combination vs. single steroid therapy in keloid disease: a comparative in vitro analysis of glucocorticoids. *Wound Repair Regen* 2013; 21: 88-102.
97. Wang J, Dodd C, Shankowsky H A et al. Deep dermal fibroblasts contribute to hypertrophic scarring. *Lab Invest* 2008; 88: 1278-1290.
98. Zhang G Y, Cheng T, Zheng M H et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. *Arch Dermatol Res* 2009; 301: 515-522.
99. Moon H, Yong H, Lee A R Optimum scratch assay condition to evaluate connective tissue growth factor expression for anti-scar therapy. *Arch Pharm Res* 2012; 35: 383-388.
100. Ong C T, Khoo Y T, Tan E K et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. *J Pathol* 2007; 211: 95-108.
101. Phan T T, Lim I J, Aalami O et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. *J Pathol* 2005; 207: 232-242.
102. Derderian C A, Bastidas N, Lerman O Z et al. Mechanical strain alters gene expression in an in vitro model of hypertrophic scarring. *Ann Plast Surg* 2005; 55: 69-75.
103. Kamamoto F, Paggiaro A O, Rodas A et al. A wound contraction experimental model for studying keloids and wound-healing modulators. *Artif Organs* 2003; 27: 701-705.

104. Linge C, Richardson J, Vigor C et al. Hypertrophic scar cells fail to undergo a form of apoptosis specific to contractile collagen—the role of tissue transglutaminase. *J Invest Dermatol* 2005; 125: 72-82.
105. Varkey M, Ding J, Tredget E E Differential collagen-glycosaminoglycan matrix remodeling by superficial and deep dermal fibroblasts: potential therapeutic targets for hypertrophic scar. *Biomaterials* 2011; 32: 7581-7591.
106. Bellemare J, Roberge C J, Bergeron D et al. Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars. *J Pathol* 2005; 206: 1-8.
107. Moulin V J Reconstitution of skin fibrosis development using a tissue engineering approach. *Methods Mol Biol* 2013; 961: 287-303.
108. Butler P D, Ly D P, Longaker M T et al. Use of organotypic coculture to study keloid biology. *Am J Surg* 2008; 195: 144-148.
109. Chiu L L, Sun C H, Yeh A T et al. Photodynamic therapy on keloid fibroblasts in tissue-engineered keratinocyte-fibroblast co-culture. *Lasers Surg Med* 2005; 37: 231-244.
110. Chua A W, Ma D, Gan S U et al. The role of R-spondin2 in keratinocyte proliferation and epidermal thickening in keloid scarring. *J Invest Dermatol* 2011; 131: 644-654.
111. Funayama E, Chodon T, Oyama A et al. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts: an important role in the pathogenesis of keloid. *J Invest Dermatol* 2003; 121: 1326-1331.
112. Khoo Y T, Ong C T, Mukhopadhyay A et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. *J Cell Physiol* 2006; 208: 336-343.
113. Lim I J, Phan T T, Tan E K et al. Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids. *J Biol Chem* 2003; 278: 40851-40858.
114. Werner S, Grose R Regulation of wound healing by growth factors and cytokines. *Physiol Rev* 2003; 83: 835-870.